Adverse Events with Sustained-Release Donepezil in Alzheimer Disease

Chunsoo Lee, Kyungsang Lee, Hyewon Yu, Seung Ho Ryu, Seok Woo Moon, Changsu Han, Jun Young Lee, Young Min Lee, Shin Gyeom Kim, Ki Woong Kim, Dong Woo Lee, Seong Yoon Kim, Sang Yeol Lee, Jae Nam Bae, Young Eun Jung, Jeong Lan Kim, Byung Soo Kim, Il Seon Shin, Young Hoon Kim, Bong Jo KimHyo Shin, Woojae Myung, Bernard J. Carroll, Doh Kwan Kim

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Purpose/Background: Sustained-releasehigh-dose (23 mg/d) donepezil has been approved for treatment of moderate to severe Alzheimer disease (AD). Based on a previous clinical trialbody weight of less than 55 kg is a risk factor for adverse events with donepezil 23 mg/d treatment in global population. Methods/Procedures: To clarify whether this finding is consistent across ethnic groups that vary in absolute body masswe recruited Korean patients aged 45 to 90 years with moderate to severe AD who had been receiving standard donepezil immediate release 10mg/d for at least 3months.

Original languageEnglish
Pages (from-to)401-404
Number of pages4
JournalJournal of Clinical Psychopharmacology
Issue number4
Publication statusPublished - 2017 Aug 1
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2017 Wolters Kluwer HealthInc. All rights reserved.


  • Alzheimer disease
  • adverse effects
  • body mass index
  • clinical trial
  • donepezil

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Adverse Events with Sustained-Release Donepezil in Alzheimer Disease'. Together they form a unique fingerprint.

Cite this